Theravance Biopharma TBPH US — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Theravance Biopharma’s 10-K, filed March 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's us — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's US — revenue?
- Theravance Biopharma (TBPH) reported US — revenue of $18.74M in Q4 2025.
- How has Theravance Biopharma's US — revenue changed year-over-year?
- Theravance Biopharma's US — revenue increased by 16.4% year-over-year, from $16.1M to $18.74M.
- What is the long-term trend for Theravance Biopharma's US — revenue?
- Over 4 years (2021 to 2025), Theravance Biopharma's US — revenue has grown at a 7.9% compound annual growth rate (CAGR), from $55.27M to $74.96M.
- What does US — revenue mean?
- This metric represents the total revenue generated from contracts with customers within the US geographic segment, excluding any assessed taxes such as sales or value-added taxes. It serves as a primary indicator of the company's commercial success and market penetration for its pharmaceutical products in the domestic market.